diagnosis analysis News
-
RemetricHealth’s Integrated Telehealth/Remote Patient Monitoring Solutions Bridge the Gap Between Patients and Providers Amid Ongoing COVID-19 Crisis
RemetricHealth, a leading remote patient monitoring (RPM) and telehealth services company that has been serving the healthcare industry for more than a decade, has announced that its telehealth capabilities, in conjunction with its biometric monitoring devices, are helping connect patients and providers in a time when continuity of care can be challenging due to COVID-19. The telehealth model is ...
-
New clinical studies published on the Nukute website
Our notified body SGS has confirmed the compliance for the Nukute Collare home sleep apnea testing (HSAT). The new intended use states the following: Nukute Collare system is intended to be used for adult patient respiratory monitoring, detection, and analysis. The acquired data is intended to be used by Healthcare professionals and the analysis may aid in the diagnosis of sleeping related ...
By Nukute Oy
-
Virusight Diagnostic Integrated into Sheba Medical Center’s Battle vs. COVID-19
Founded in 2020 in response to the COVID-19 pandemic, Virusight, which is an AI software company, was created to develop an accurate, real-time virus diagnosis solution. The company uses unique spectral acquisition and analysis technology, for pathogenic diagnosis. The company is currently in the midst of developing and testing revolutionary COVID-19 rapid tests, based on Newsight ...
By Virusight
-
CD Bioparticles Launches NIR-Quantum Dots for Biomedical Imaging
With years of experience in the pharmaceutical and life science sector, CD Bioparticles launched a range of near-infra-red (NIR) quantum dots that exhibit excellent optical properties and biocompatibility for biomedical imaging. Currently, CD Bioparticles has successfully synthesized a variety of NIR quantum dots, including PbS/CdS, PbS, PbSe, Ag2S, CuInS/ZnS, and CdTe/CdSe/ZnS. Quantum points ...
-
Biotricity to launch commercial sales of its disruptive cardiac monitoring device, Biotres in April 2022
Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, will officially launch the commercial sales of its FDA cleared, wireless wearable cardiac monitoring device, Biotres, in April 2022. The product has been available for pre-orders to physicians, medical offices, hospitals and individual use since ...
-
Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced new clinical validation data for their thyroid cancer test platform which is comprised of a mutation panel ...
-
Fasha Mahjoor, Phenomenex CEO, Appointed to Outward Bound’s 25 Strong Chairman’s Group
Fasha Mahjoor, founder and CEO of Phenomenex, a global leader in the separation sciences, has been appointed as one of “Outward Bound Trust’s 25 Strong Chairman’s Group members.” This newly formed team will meet in early June at Buckingham Palace with Outward Bound’s Chairman, HRH Duke of York, Prince Andrew. Helping over a million young ...
-
ConcertAI’s TeraRecon Accelerates Multi-Specialty Advanced Visualization Capabilities with the Launch of Intuition 4.6
TeraRecon, a ConcertAI company and a leader in advanced medical visualization to improve patient care, today announced the global launch of Intuition 4.6 at the European Congress of Radiology in Vienna, Austria. "Intuition 4.6 brings a comprehensive set of improvements to our award-winning AV software solution, many of which came as a direct result with collaborations with practitioners," said ...
-
Fasha (Farshad) Mahjoor, Phenomenex CEO, to Jump off 87th Floor of Skyscraper
Fasha Mahjoor, founder and CEO of Phenomenex, a separation sciences company, will leap off the 87th floor of The Shard in London, Europe’s tallest building, on the 3rd of September to raise funds for The Outward Bound Trust. Alongside a handful of other adventurous philanthropists and led by the Chairman of The Outward Bound Trust, His Royal Highness The Duke of York, Prince Andrew, the ...
-
Creative Proteomics Upgraded Exosome Proteomics Service to Accelerate Biomarker Discovery Research
Creative Proteomics, an integrated CRO company committed to providing a full range of services to support various proteome-related research projects from identification of single proteins to large-scale proteomic studies, has recently upgraded its fully-developed Exosome Proteomics Service to identify and quantify the proteins in exosomes. The company can also help discover biomarkers after ...
-
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2022 and provided a business and financial update. Second quarter Net Revenue was $9.4 million, a 16% decrease as compared to the same period of 2021. During the second quarter the Company was notified by Novitas, it’s CME ...
-
Thermo Fisher Scientific Introduces Hematology-Oncology Portfolio for Ion Torrent Genexus System
In hematology oncology, it is critically important to understand the genetics driving acute malignancies to quickly determine how best to address the disease. Today, Thermo Fisher Scientific announces a new portfolio of hematology-oncology assays for the Ion Torrent Genexus System* designed to enable a future in which turnaround times for next-generation sequencing (NGS) results can be reduced to ...
-
Med Tech Outlook: Top Medical Ventilator Solution Providers 2021
Accurate breath analysis is key for diagnosis and assessment of pulmonary illnesses. Breath analysis is an important evaluation tool to support respiratory therapists and pulmonologists in the diagnosis and treatment of varying respiratory illnesses. Unfortunately, moisture is an impediment to successful breath analysis. Moisture in breath samples can adversely impact the accuracy of breath ...
-
Oxford Brain Diagnostics establishes a research-based clinical MRI study in Japan to investigate how Cortical Disarray Measurement (CDM) analysis may support differential diagnosis and estimate disease severity in Dementia patients
Oxford Brain Diagnostics Ltd, a software company focused on developing diagnostics based on changes in the brain at the cellular level, is delighted to announce that we have established a research collaboration with Principal Investigator Dr Takashi Nakajima, MD, PhD at Niigata Hospital and Dr Kazuo Shigematsu at Minami Kyoto National Hospital. In Japan, clinical MRI scanners are available for ...
-
Bayer acquires Blackford Analysis Ltd. bolstering the company’s position in digital medical imaging
Acquisition is part of Bayer’s innovation strategy in radiology Blackford Analysis provides cutting-edge radiology AI (artificial intelligence) platform technology Following closing of the acquisition, Blackford Analysis to become part of Bayer’s well established “arm’s length” operating model to preserve the company’s entrepreneurial culture Bayer today ...
By Bayer AG
-
Virusight Diagnostic’s solution for instant COVID-19 screening demonstrates high correlation to PCR in pre-clinical testing in Spain and company signs an MOU for 50 million tests in APAC
Virusight Diagnostic, A JV of Newsight Imaging and Sheba Medical Center with 26 active pilots in leading hospitals around the world, files for regulation approvals The pre-clinical testing has been performed by Microbiology and Molecular departments at leading hospitals in area of Madrid, Castilla-La Mancha and Castilla -León regions and included hundreds of real swab samples of ...
By Virusight
-
Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease
Clinical data demonstrating initial safety and efficacy from the RESKUE trial are being presented by Chief Medical Officer Maria Escolar, M.D., at the 29th Congress of European Society of Gene & Cell Therapy (ESGCT), October 11-14, 2022 Subjects treated with FBX-101 have shown increased galactocerebrosidase (GALC) enzyme activity in plasma and cerebrospinal fluid (CSF), normal white matter ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you